| GTO ID | GTC1178 |
| Trial ID | NCT00006480 |
| Disease | Neuroblastoma |
| Altered gene | CE7R|Hytk |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | therapeutic autologous lymphocytes |
| Co-treatment | aldesleukin|chemotherapy|ganciclovir |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase I Study to Evaluate the Safety of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Genetically-Modified Autologous CD8+ T Cell Clones |
| Year | 2000 |
| Country | United States |
| Company sponsor | Fred Hutchinson Cancer Center |
| Other ID(s) | 1524.00|FHCRC-1524.00|NCI-H00-0065|CDR0000068310 |
| Cohort 1 | |||||
|
|||||